Global Information
회사소개 | 문의

마취 효과 : 파이프라인 리뷰

Anesthetic Effect - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 253649
페이지 정보 영문 82 Pages
가격
US $ 2,000 ₩ 2,287,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,575,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,863,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


마취 효과 : 파이프라인 리뷰 Anesthetic Effect - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 82 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

마취 효과에 의해 의식이 상실됩니다. 합병증의 위험을 높이는 주요인으로서 흡연, 폐색형 수면시 무호흡 증후군, 비만, 고혈압, 마취 부작용 병력, 의약품 알레르기 체질 등을 들 수 있습니다.

세계 각국에서의 마취 효과(Anesthetic Effect) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시의 최신 동향, 임상시험 각 단계별 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

마취 효과 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업에서 개발중인 치료제
  • 대학/기관에서 연구중인 치료제
  • 기업에서 개발중인 제품
  • 대학/기관에서 연구중인 제품

마취 효과 : 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

마취 효과 치료제 개발 참여 기업

  • 4P Therapeutics LLC
  • Biolab Farmaceutica Ltda
  • Drawbridge Pharmaceuticals Pty Ltd
  • Expanesthetics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Lee's Pharmaceutical Holdings Ltd
  • Lipicard Technologies Ltd
  • NanoMedex Pharmaceuticals Inc
  • Paion AG
  • Phosphagenics Ltd
  • Physica Pharma
  • Primex Pharmaceuticals Oy
  • Proteus SA
  • Sphaera Pharma Pvt Ltd
  • Taiwan Liposome Company Ltd
  • The Medicines Company
  • WEX Pharmaceuticals Inc

치료제 개요

마취 효과 : 휴지 상태인 프로젝트

마취 효과 : 개발이 중지된 제품

마취 효과 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 17.04.24

List of Tables

  • Number of Products under Development for Anesthetic Effect, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H2 2018
  • Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H2 2018
  • Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2018
  • Anesthetic Effect - Pipeline by Expanesthetics Inc, H2 2018
  • Anesthetic Effect - Pipeline by Grunenthal GmbH, H2 2018
  • Anesthetic Effect - Pipeline by Lannett Company Inc, H2 2018
  • Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
  • Anesthetic Effect - Pipeline by MedinCell SA, H2 2018
  • Anesthetic Effect - Pipeline by Paion AG, H2 2018
  • Anesthetic Effect - Pipeline by Phosphagenics Ltd, H2 2018
  • Anesthetic Effect - Pipeline by Physica Pharma, H2 2018
  • Anesthetic Effect - Pipeline by Recro Pharma Inc, H2 2018
  • Anesthetic Effect - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2018
  • Anesthetic Effect - Pipeline by SiteOne Therapeutics Inc, H2 2018
  • Anesthetic Effect - Pipeline by Sphaera Pharma Pte Ltd, H2 2018
  • Anesthetic Effect - Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H2 2018
  • Anesthetic Effect - Dormant Projects, H2 2018
  • Anesthetic Effect - Dormant Projects, H2 2018 (Contd..1), H2 2018
  • Anesthetic Effect - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Anesthetic Effect, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2018, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 4, 2, 2, 1, 9, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anesthetic Effect - Overview
    • Anesthetic Effect - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Anesthetic Effect - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Anesthetic Effect - Companies Involved in Therapeutics Development
    • Biolab Farmaceutica Ltda
    • Crescita Therapeutics Inc
    • Drawbridge Pharmaceuticals Pty Ltd
    • Expanesthetics Inc
    • Grunenthal GmbH
    • Lannett Company Inc
    • Lee's Pharmaceutical Holdings Ltd
    • MedinCell SA
    • Paion AG
    • Phosphagenics Ltd
    • Physica Pharma
    • Recro Pharma Inc
    • Sichuan Kelun Pharmaceutical Co Ltd
    • SiteOne Therapeutics Inc
    • Sphaera Pharma Pte Ltd
    • YiChang Humanwell Pharmaceutical Co Ltd
  • Anesthetic Effect - Drug Profiles
    • (bupivacaine + neosaxitoxin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lidocaine + prilocaine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alphaxalone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aom-0498 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aom-0765 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cysteine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXPS-09 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Flexicaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fospropofol disodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSK-3486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KL-100137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDC-CMV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHY-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block NaV1.7 for Local Anesthetic Effect - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPR-819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anesthetic Effect - Dormant Projects
  • Anesthetic Effect - Discontinued Products
  • Anesthetic Effect - Product Development Milestones
    • Featured News & Press Releases
      • Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea
      • Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia
      • Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
      • Mar 20, 2018: Phosphagenics/Terumo R&D alliance to focus on TPM Injectables: TPM/Oxymorphone Patch Development to move outside Agreement
      • Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Korea
      • Nov 09, 2017: Phosphagenics Provides Update on TPM/Propofol Development Program
      • Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU
      • Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
      • Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia
      • Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
      • Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
      • Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
      • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
      • Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
      • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
이용안내
 
BCC Research